Humacyte, Inc. (HUMA)
| Market Cap | 167.85M -19.8% |
| Revenue (ttm) | 2.04M |
| Net Income | -40.83M |
| EPS | -0.26 |
| Shares Out | 222.02M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 484,177 |
| Open | 0.7133 |
| Previous Close | 0.7049 |
| Day's Range | 0.7133 - 0.7599 |
| 52-Week Range | 0.5469 - 2.9300 |
| Beta | 2.10 |
| Analysts | Strong Buy |
| Price Target | 6.19 (+718.78%) |
| Earnings Date | May 12, 2026 |
About HUMA
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would tar... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for HUMA stock is "Strong Buy." The 12-month stock price target is $6.19, which is an increase of 718.78% from the latest price.
News
Humacyte Appoints Jim Mercadante as Chief Commercial Officer
– Industry veteran with more than 25 years of experience will lead next phase of biotech company's commercial expansion – – Seasoned medtech commercial leader brings extensive field-specific success i...
Humacyte Announces Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess® for Vascular Trauma Repair
- The Ministry of Health has set a 180-working-day review period for the MAA - - MAA process is one step in planned expansion of Symvess into multiple countries outside of the U.S - DURHAM, N.C., Apr...
Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has comm...
Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update
- Total revenues from sales and research collaborations were $0.5 million for fourth quarter and $2.0 million for full year -
Humacyte Appoints Rick McElheny as Senior Vice President of Business Development
- Mr. McElheney brings more than 15 of years' experience in corporate development and alliance management at biopharma companies. - - He will work with the Company's leadership team to expand corpora...
Humacyte To Announce 2025 Fourth Quarter and Year End Financial Results and Provide Business Update on March 27, 2026
DURHAM, N.C., March 23, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at com...
Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common Stock
Net proceeds from the offering will fund the commercialization of Symvess® in the vascular trauma indication and provide funding beyond key milestones such as the upcoming read-out of Phase 3 results ...
Humacyte Submits Marketing Authorization Application for Symvess® in Israel for Vascular Trauma Repair
- Humacyte is also pursuing a mechanism for making Symvess available in Israel on a hospital-by-hospital basis in advance of MAA approval - - Preparation is underway for expansion of Symvess into oth...
Humacyte To Participate in Upcoming Investor Conferences
DURHAM, N.C., March 02, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at com...
Humacyte Announces Presentation of Symvess® Long-Term Safety and Efficacy Results at VESS Meeting
- Data presented at Annual Winter Meeting 2026 for the Vascular & Endovascular Surgery Society - - After up to 36 months of follow-up, extremity arterial trauma patients had high rates of limb salvag...
Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels
DURHAM, N.C., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at comm...
Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications
- Data is from comprehensive review of hospital charges and all-payer claims over five years - - Preventable complications such as amputation and conduit infection increased initial hospital charges ...
Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel
- Expansion plans are based on requests for product access received from surgeons and hospitals in Israel - - Expansion of Symvess into other territories, including those in Europe and the Middle Eas...
Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair
- Results published in Journal of Vascular Surgery Cases, Innovations and Techniques (JVS-CIT) - - After up to 36 months of follow-up, patients demonstrated high limb salvage, low rates of infection,...
Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital
DURHAM, N.C., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at comm...
Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV™) Clinical Results
– Post-implantation analysis of ATEVs demonstrates progressive recellularization with host cells, transforming the ATEV into a multi-layered living tissue similar to that of native blood vessels – ...
Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium)
DURHAM, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at comm...
Humacyte Announces Third Quarter 2025 Financial Results and Provides Business Update
- Total revenues of $753,000 for third quarter, and $1,571,000 for first nine months of 2025, from sales and collaborative research agreement - - Major advances in pipeline as Humacyte moves closer t...
Humacyte Announces Presentation of Positive Two-Year Results from Phase 3 Dialysis Access Trial at the American Society of Nephrology's Kidney Week 2025
– The ATEV™ was observed to have superior duration of use over 24 months compared to autogenous fistula in high-need subgroups with historically poor outcomes with AV fistula procedures – – The signif...
Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025
DURHAM, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commerc...
Humacyte Announces Publication of New Data Comparing Symvess™ to Autologous Vein in Extremity Arterial Trauma
- Results published in AAST's Trauma Surgery & Acute Care Open Journal - - Study compared outcomes of patients treated with Symvess with patients in PROOVIT registry who were treated with vein - - In ...
Humacyte Announces Pricing of $60.0 Million Oversubscribed Registered Direct Offering
DURHAM, N.C., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at comm...
Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess™
- Results published in Oxford Academic's Military Medicine Journal - - After up to 18 months of follow-up patients were observed to have zero infections, amputations or deaths and a high rate of paten...
Humacyte Announces Expansion of Intellectual Property for Pipeline Products with Granting of New U.S. Patent for Bioengineered Esophagus
– Patent covers esophagus produced using Humacyte's proprietary bioengineered regenerative tissue platform, designed for implant in patients with damaged esophagus – – Patent provides coverage into 20...